VCA Stocks

Quark Pharmaceuticals, Inc., a development-stage pharmaceutical company focused on discovering and developing novel RNA interference-based therapeutics, today announced the closing of a private financing totaling an aggregate of $27 million.  Quark’s current clinical pipeline includes AKIi-5, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery, currently in Phase I/IIa clinical trials via systemic delivery. Based on publicly available information, Quark believes this was the first siRNA delivered systemically in a human clinical trial.  In addition to AKIi-5, Quark’s lead compound, RTP801i-14, licensed to Pfizer on an exclusive worldwide basis, is completing Phase I/IIa trials for wet age-related macular degeneration (AMD). Quark expects its partner, Pfizer, to continue to progress RTP801i-14 through Phase II clinical trials for the treatment of AMD and diabetic macular edema (DME).